Source link : https://www.newshealth.biz/health-news/tirzepatide-officially-puts-glp-1-meds-on-the-map-for-obesity-related-heart-failure/
CHICAGO — A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial. Incident cardiovascular death or worsening heart failure (HF) events were down over a median 104 weeks of follow-up in people who had been randomized to tirzepatide […]
Author : News Health
Publish date : 2024-11-16 21:43:07
Copyright for syndicated content belongs to the linked Source.